



28 August 2018

**Nuformix plc**  
("Nuformix" or the "Company")

### **Renewal of Loan Notes**

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has agreed to amend the terms of the Convertible Loan Agreement ("Loan") dated 18th April 2017, extending the loan until 18th April 2019.

The conversion price of any outstanding loans and any accrued interest into shares and warrants has been set at 2.75p per share and such warrants are exercisable at any time for 60 months from the date on which the warrants were granted. The 2.75p conversion price represents a 8% premium to the closing price on 23 August 2018, the day prior to the amended agreement being signed.

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

#### **Enquiries:**

**Nuformix plc**  
Dr Dan Gooding, Chief Executive Officer

+44 (0)1223 423667

**Gable Communications Ltd**  
John Bick / Justine James

+44 (0)20 7193 7463

#### **About Nuformix plc [www.nuformix.com](http://www.nuformix.com)**

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.